1 Department of Clinical Biochemistry, Herlev and Gentofte Hospital.
3 The Copenhagen General Population Study, Herlev and Gentofte Hospital, and.
Am J Respir Crit Care Med. 2016 May 1;193(9):965-74. doi: 10.1164/rccm.201509-1869OC.
Whether high blood eosinophils are associated with chronic obstructive pulmonary disease (COPD) exacerbations among individuals with COPD in the general population is largely unknown.
To test the hypothesis that high blood eosinophils predict COPD exacerbations.
Among 81,668 individuals in the Copenhagen General Population Study, we examined 7,225 with COPD based on spirometry. We recorded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (short-course treatment with systemic corticosteroids) or severe (hospitalization). We also assessed exacerbation risk in a subgroup of 203 individuals with clinical COPD, defined as participants with a smoking history of at least 10 pack-years, FEV1 less than 70% of predicted value, and at least one moderate or severe exacerbation in the year before baseline.
During a median of 3.3 years of follow-up (range, 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded. Among all participants with COPD, blood eosinophils above versus below 0.34 × 10(9) cells per liter had multivariable-adjusted incidence rate ratios of 1.76 (95% confidence interval, 1.56-1.99) for severe exacerbations and 1.15 (1.05-1.27) for moderate exacerbations. Corresponding values in those with clinical COPD were 3.21 (2.49-4.14) and 1.69 (1.40-2.04). In contrast, using a cutpoint of 2% for blood eosinophils, the risk of exacerbations was increased for severe exacerbations only among individuals with clinical COPD and not in individuals in the broader population.
Among individuals with COPD in the general population, increased blood eosinophil levels above 0.34 × 10(9) cells per liter were associated with a 1.76-fold increased risk of severe exacerbations.
在普通人群中,高血嗜酸性粒细胞是否与慢性阻塞性肺疾病(COPD)加重有关尚不清楚。
检验高血嗜酸性粒细胞是否能预测 COPD 加重的假说。
在哥本哈根普通人群研究中,我们对 81668 名人群进行了研究,其中 7225 人通过肺量测定法被诊断为 COPD。我们在基线时和未来的 COPD 加重期间(定义为中重度(短期全身皮质激素治疗)或重度(住院))纵向检测了血嗜酸性粒细胞。我们还在一个由 203 名患有临床 COPD 的个体组成的亚组中评估了加重风险,这些个体的特征为吸烟史至少 10 包年,FEV1 低于预计值的 70%,且在基线前一年至少有一次中重度或重度加重。
在中位数为 3.3 年的随访期间(范围:0.03-8.1 年),记录了 1439 例重度和 2864 例中度 COPD 加重。在所有患有 COPD 的参与者中,血嗜酸性粒细胞高于或低于 0.34×10(9)个细胞/升的个体,重度加重的多变量调整发病率比为 1.76(95%置信区间,1.56-1.99),中度加重的发病率比为 1.15(1.05-1.27)。在患有临床 COPD 的个体中,相应的值分别为 3.21(2.49-4.14)和 1.69(1.40-2.04)。相比之下,当使用血嗜酸性粒细胞 2%作为切点时,只有在患有临床 COPD 的个体中,重度加重的风险增加,而在更广泛的人群中则没有。
在普通人群中患有 COPD 的个体中,血嗜酸性粒细胞水平高于 0.34×10(9)个细胞/升与重度加重的风险增加 1.76 倍相关。